{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T13:49:22Z","timestamp":1776779362930,"version":"3.51.2"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Virginia Commonwealth University REDCap Grant","award":["UL1TR002649"],"award-info":[{"award-number":["UL1TR002649"]}]},{"name":"VCU Massey Cancer Center Biostatistics Shared Resource","award":["P30 CA016059"],"award-info":[{"award-number":["P30 CA016059"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-024-02302-y","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T12:03:02Z","timestamp":1708689782000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Venetoclax with decitabine or azacitidine in relapsed or refractory acute myeloid leukemia"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4274-4249","authenticated-orcid":false,"given":"Ian M.","family":"Bouligny","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graeme","family":"Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Doyel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tilak","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josh","family":"Boron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juhi","family":"Gor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiwei","family":"Hang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanal","family":"Alnimer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thuy","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle","family":"Zacholski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chad","family":"Venn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nolan A.","family":"Wages","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Grant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keri R.","family":"Maher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"key":"2302_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.663","author":"IM Bouligny","year":"2022","unstructured":"Bouligny IM, Maher KR, Grant S. Mechanisms of myeloid leukemogenesis: current perspectives and therapeutic objectives. Blood Rev. 2022. https:\/\/doi.org\/10.1002\/jha2.663.","journal-title":"Blood Rev"},{"issue":"7","key":"2302_CR2","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617\u201329.","journal-title":"N Engl J Med"},{"issue":"3","key":"2302_CR3","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1634\/theoncologist.10-3-176","volume":"10","author":"E Kaminskas","year":"2005","unstructured":"Kaminskas E, et al. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist. 2005;10(3):176\u201382.","journal-title":"Oncologist"},{"issue":"4","key":"2302_CR4","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","volume":"28","author":"P Fenaux","year":"2010","unstructured":"Fenaux P, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28(4):562\u20139.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2302_CR5","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1002\/cncr.21792","volume":"106","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106(8):1794\u2013803.","journal-title":"Cancer"},{"key":"2302_CR6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, et al. Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel. Blood. 2022. https:\/\/doi.org\/10.1182\/blood.2022016867.","journal-title":"Blood"},{"issue":"102","key":"2302_CR7","doi-asserted-by":"publisher","first-page":"37777","DOI":"10.18632\/oncotarget.26540","volume":"9","author":"M Grundy","year":"2018","unstructured":"Grundy M, et al. Genetic biomarkers predict response to dual BCL-2 and MCL-1 targeting in acute myeloid leukaemia cells. Oncotarget. 2018;9(102):37777\u201389.","journal-title":"Oncotarget"},{"issue":"11","key":"2302_CR8","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135(11):791\u2013803.","journal-title":"Blood"},{"issue":"Supplement 1","key":"2302_CR9","doi-asserted-by":"publisher","first-page":"6335","DOI":"10.1182\/blood-2022-170907","volume":"140","author":"IM Bouligny","year":"2022","unstructured":"Bouligny IM, et al. IDH1\/2mut for the win: comprehensive molecular stratification of venetoclax in combination with hypomethylating agents in AML. Blood. 2022;140(Supplement 1):6335\u20136.","journal-title":"Blood"},{"key":"2302_CR10","first-page":"100996","volume":"383","author":"IM Bouligny","year":"2023","unstructured":"Bouligny IM, et al. Venetoclax with decitabine or azacitidine in the first-line treatment of acute myeloid leukemia. eJHaem. 2023;383:100996.","journal-title":"eJHaem"},{"issue":"24","key":"2302_CR11","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1182\/blood-2008-12-196055","volume":"114","author":"G Yoshimoto","year":"2009","unstructured":"Yoshimoto G, et al. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. Blood. 2009;114(24):5034\u201343.","journal-title":"Blood"},{"issue":"9","key":"2302_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2017.1283032","volume":"58","author":"P Bose","year":"2017","unstructured":"Bose P, Gandhi V, Konopleva M. Pathways and mechanisms of venetoclax resistance. Leuk Lymphoma. 2017;58(9):1\u201317.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2302_CR13","doi-asserted-by":"publisher","first-page":"380","DOI":"10.20517\/cdr.2021.125","volume":"5","author":"F Ong","year":"2022","unstructured":"Ong F, Kim K, Konopleva MY. Venetoclax resistance: mechanistic insights and future strategies. Cancer Drug Resist. 2022;5(2):380\u2013400.","journal-title":"Cancer Drug Resist"},{"key":"2302_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14082025","author":"S Garciaz","year":"2022","unstructured":"Garciaz S, et al. Azacitidine plus venetoclax for the treatment of relapsed and newly diagnosed acute myeloid leukemia patients. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14082025.","journal-title":"Cancers (Basel)"},{"issue":"18","key":"2302_CR15","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728\u201340.","journal-title":"N Engl J Med"},{"issue":"16","key":"2302_CR16","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","volume":"386","author":"P Montesinos","year":"2022","unstructured":"Montesinos P, et al. Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. N Engl J Med. 2022;386(16):1519\u201331.","journal-title":"N Engl J Med"},{"issue":"1","key":"2302_CR17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41408-021-00604-2","volume":"12","author":"S Venugopal","year":"2022","unstructured":"Venugopal S, et al. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Blood Cancer J. 2022;12(1):10.","journal-title":"Blood Cancer J"},{"issue":"11","key":"2302_CR18","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","volume":"47","author":"M Charlson","year":"1994","unstructured":"Charlson M, et al. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245\u201351.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"2302_CR19","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, et al. Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"key":"2302_CR20","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 11\/27\/2017 January 25, 2018 [cited 2021 February 1]."},{"key":"2302_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95: 103208.","journal-title":"J Biomed Inform"},{"issue":"20","key":"2302_CR22","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood"},{"issue":"26","key":"2302_CR23","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021;138(26):2753\u201367.","journal-title":"Blood"},{"issue":"24","key":"2302_CR24","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21(24):4642\u20139.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2302_CR25","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner H, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424\u201347.","journal-title":"Blood"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-024-02302-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-024-02302-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-024-02302-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:03:58Z","timestamp":1709078638000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-024-02302-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["2302"],"URL":"https:\/\/doi.org\/10.1007\/s12032-024-02302-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3015916\/v1","asserted-by":"object"}]},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,23]]},"assertion":[{"value":"2 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K.R. Maher is a consultant for Sobi and Bristol-Myers Squibb. The remaining authors have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"80"}}